IM Reports Results of IMT-002 in P-Ib MAD Trial for the Treatment of Type 1 Diabetes

 IM Reports Results of IMT-002 in P-Ib MAD Trial for the Treatment of Type 1 Diabetes

IM Reports Results of IMT-002 in P-Ib MAD Trial for the Treatment of Type 1 Diabetes

Shots:

  • The P-Ib MAD trial involves assessing IMT-002 (350 /1050 mg, qd/bid over a 2wks.) vs PBO in 30 T1D patients preselected for HLA-DQ8 aged b/w 18-45yrs. and were interspersed in the 4 groups and involves a 1wk. follow-up after dose completion
  • The therapy was safe & well-tolerated with no SAEs & did not increase with dose. PK were followed for (1050mg, qd) & (350/700/1050mg, bid) over 24-hrs. after drug administration, IMT-002 (bid regimen) showed increase in Cmax & high Ctrough @4hrs. while qd dose showed low Cmax & Ctrough
  • IMT-002 targets HLA-DQ8 to prevent the immune system from attacking insulin-producing beta cells. The company is planning to advance the therapy in the P-II study

Click here to­ read full press release/ article | Ref: Businesswire | Image: IM Therapeutics

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post